Wu Y - Search Results

1

Design, synthesis, and evaluation of quinolin-2(1H)-ones as PDE1 inhibitors for the treatment of inflammatory bowel disease.

Zhou Q, Luo WH, Zhang B, Xue ZH, Huang QH, Feng LL, Wu Y, Zhang C. Zhou Q, et al. Among authors: wu y. Bioorg Chem. 2025 Jan;154:107979. doi: 10.1016/j.bioorg.2024.107979. Epub 2024 Nov 19. Bioorg Chem. 2025. PMID: 39603073

2

Palladium-Catalyzed Decarboxylative Acylation of N-Nitrosoanilines with α-Oxocarboxylic Acids.

Wu Y, Sun L, Chen Y, Zhou Q, Huang JW, Miao H, Luo HB. Wu Y, et al. J Org Chem. 2016 Feb 5;81(3):1244-50. doi: 10.1021/acs.joc.5b02535. Epub 2016 Jan 19. J Org Chem. 2016. PMID: 26746881

3

3D-QSAR studies of 3-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic acids as AKR1C3 inhibitors: Highlight the importance of molecular docking in conformation generation.

Zheng X, Wu Y, Wu D, Wang X, Zhang C, Guo X, Luo HB. Zheng X, et al. Among authors: wu y, wu d. Bioorg Med Chem Lett. 2016 Dec 1;26(23):5631-5638. doi: 10.1016/j.bmcl.2016.10.073. Epub 2016 Nov 1. Bioorg Med Chem Lett. 2016. PMID: 27847272

4

Discovery of Novel Phosphodiesterase-2A Inhibitors by Structure-Based Virtual Screening, Structural Optimization, and Bioassay.

Zhang C, Feng LJ, Huang Y, Wu D, Li Z, Zhou Q, Wu Y, Luo HB. Zhang C, et al. Among authors: wu y, wu d. J Chem Inf Model. 2017 Feb 27;57(2):355-364. doi: 10.1021/acs.jcim.6b00551. Epub 2017 Jan 18. J Chem Inf Model. 2017. PMID: 28055196

5

Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension.

Wu D, Zhang T, Chen Y, Huang Y, Geng H, Yu Y, Zhang C, Lai Z, Wu Y, Guo X, Chen J, Luo HB. Wu D, et al. Among authors: wu y. J Med Chem. 2017 Aug 10;60(15):6622-6637. doi: 10.1021/acs.jmedchem.7b00523. Epub 2017 Jul 25. J Med Chem. 2017. PMID: 28686445

6

Discovery of Novel Pyrazolopyrimidinone Derivatives as Phosphodiesterase 9A Inhibitors Capable of Inhibiting Butyrylcholinesterase for Treatment of Alzheimer's Disease.

Yu YF, Huang YD, Zhang C, Wu XN, Zhou Q, Wu D, Wu Y, Luo HB. Yu YF, et al. Among authors: wu y, wu d, wu xn. ACS Chem Neurosci. 2017 Nov 15;8(11):2522-2534. doi: 10.1021/acschemneuro.7b00268. Epub 2017 Aug 23. ACS Chem Neurosci. 2017. PMID: 28783948

7

Docking-assisted 3D-QSAR studies on xanthones as α-glucosidase inhibitors.

Zheng X, Zhou S, Zhang C, Wu D, Luo HB, Wu Y. Zheng X, et al. Among authors: wu y, wu d. J Mol Model. 2017 Aug 31;23(9):272. doi: 10.1007/s00894-017-3438-1. J Mol Model. 2017. PMID: 28861624

8

Discovery of novel PDE9A inhibitors with antioxidant activities for treatment of Alzheimer's disease.

Zhang C, Zhou Q, Wu XN, Huang YD, Zhou J, Lai Z, Wu Y, Luo HB. Zhang C, et al. Among authors: wu y, wu xn. J Enzyme Inhib Med Chem. 2018 Dec;33(1):260-270. doi: 10.1080/14756366.2017.1412315. J Enzyme Inhib Med Chem. 2018. PMID: 29271265 Free PMC article.

9

Structure-Based Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel PDE10 Inhibitors With Antioxidant Activities.

Li J, Chen JY, Deng YL, Zhou Q, Wu Y, Wu D, Luo HB. Li J, et al. Among authors: wu y, wu d. Front Chem. 2018 May 15;6:167. doi: 10.3389/fchem.2018.00167. eCollection 2018. Front Chem. 2018. PMID: 29868568 Free PMC article.

10

Structure-based design, synthesis, and biological evaluation of novel pyrimidinone derivatives as PDE9 inhibitors.

Wu XN, Huang YD, Li JX, Yu YF, Qian Z, Zhang C, Wu Y, Luo HB. Wu XN, et al. Among authors: wu y. Acta Pharm Sin B. 2018 Jul;8(4):615-628. doi: 10.1016/j.apsb.2017.12.007. Epub 2018 Mar 12. Acta Pharm Sin B. 2018. PMID: 30109185 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

86,339 results

Search Page

Filters